Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
Seres Therapeutics (MCRB) Misses Q1 EPS by 9c
May 4, 2022 7:17 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $8.48 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More